Rick Lifsitz and Larry Blandford address market access for novel Alzheimer’s treatments in a new commentary for Journal of Clinical Pathways
This case study illustrates a successful program that led to 7 major national health plans offering the manufacturer’s top 2 brands at $0 out-of-pocket to the patient.
Precision for Value’s Dan Renick offers his perspective on GSK’s Breo in The Pink Sheet.
Dan Renick comments on the importance of value demonstration for respiratory disease treatments in The Pink Sheet.
(more…)
Pharma Industry Firm Moves for More Space
Precision for Value, a company that helps bring pharmaceutical products to market, has found a larger home at One Grand Central Place.
ISPOR Annual International Meeting
Precision will be exhibiting in booth 81/82
Location: Washington, D.C.
Los Angeles, May 17, 2016 — Precision Health Economics (PHE), a global leader in health economic research, policy, and analytics, announced today that Peter Neumann, ScD has joined PHE in the role of principal scientific advisor.
Precision’s Chandra and Shafrin Address Value Frameworks in JAMA
In this study, the Precision Health Economics team quantifies how patients value new oncology therapies through research focused on 2 clinical contexts in advanced cancer: metastatic malignant melanoma and metastatic breast cancer.
We are pleased to present the second installment in our recurring column, Pharma Insights. This month we take a look at an interesting twist in how the use of complementary and companion diagnostics is playing out in real-world clinical practice. In a health care system that increasingly seeks to more precisely target therapeutic approaches to diseases, diagnostic testing is the key to unlocking greater value in pharmacotherapy. Two classes of diagnostic tests—companion and complementary diagnostics—have emerged to address this need.